Aura Biosciences (AURA) Common Equity (2020 - 2026)
Aura Biosciences' (AURA) quarterly Common Equity came in at $107.2 million in Q1 2026, down 16.19% YoY from $128.0 million in Q1 2025, and down 21.67% on a QoQ basis from $136.9 million in Q4 2025.
Aura Biosciences (AURA) Common Equity (2020 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 7 years of Common Equity data on file, last reported at $107.2 million in Q1 2026.
- Quarterly Common Equity fell 16.19% year-over-year to $107.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.2 million (down 16.19% YoY) and the FY2025 annual result came in at $136.9 million, down 9.91% from the prior year.
- Common Equity fell to $107.2 million in Q1 2026, from $136.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $225.8 million in Q4 2023 to a low of $107.2 million in Q1 2026.
- A 5-year average of $160.9 million and a median of $156.7 million in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity soared 223.55% — and 2025, when it slumped 38.71%.
- Tracing AURA's Common Equity over 5 years: stood at $195.6 million in 2022, then increased by 15.47% to $225.8 million in 2023, then plunged by 32.71% to $152.0 million in 2024, then fell by 9.91% to $136.9 million in 2025, then slipped by 21.67% to $107.2 million in 2026.
- The last three Common Equity figures came in at $107.2 million (Q1 2026), $136.9 million (Q4 2025), and $156.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | 315.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 315.27 Mn |
| Mar 31, 2026 | 107.25 Mn |
| Dec 31, 2025 | 136.91 Mn |
| Sep 30, 2025 | 156.67 Mn |
| Jun 30, 2025 | 174.63 Mn |
| Mar 31, 2025 | 127.97 Mn |
| Dec 31, 2024 | 151.97 Mn |
| Sep 30, 2024 | 174.67 Mn |
| Jun 30, 2024 | 191.45 Mn |
| Mar 31, 2024 | 208.78 Mn |
| Dec 31, 2023 | 225.85 Mn |
| Sep 30, 2023 | 151.72 Mn |
| Jun 30, 2023 | 166.44 Mn |
| Mar 31, 2023 | 180.26 Mn |
| Dec 31, 2022 | 195.58 Mn |
| Sep 30, 2022 | 115.05 Mn |
| Jun 30, 2022 | 129.09 Mn |
| Mar 31, 2022 | 141.09 Mn |
| Dec 31, 2021 | 152.32 Mn |
| Sep 30, 2021 | -131.02 Mn |